门静脉高压的病理生理学及其临床关联。
Pathophysiology of portal hypertension and its clinical links.
作者信息
Seo Yeon Seok, Shah Vijay H
机构信息
Gastroenterology Research Unit, Mayo Clinic, Rochester, MN - 55905, USA.
Gastroenterology Research Unit, Mayo Clinic, Rochester, MN - 55905, USA ; Mayo Clinic Center for Cell Signaling in Gastroenterology, Mayo Clinic, Rochester, MN - 55905, USA.
出版信息
J Clin Exp Hepatol. 2011 Sep;1(2):87-93. doi: 10.1016/S0973-6883(11)60127-8. Epub 2011 Nov 9.
Abstract
Portal hypertension is a major cause of morbidity and mortality in patients with liver cirrhosis. Intrahepatic vascular resistance due to architectural distortion and intrahepatic vasoconstriction, increased portal blood flow due to splanchnic vasodilatation, and development of collateral circulation have been considered as major factors for the development of portal hypertension. Recently, sinusoidal remodeling and angiogenesis have been focused as potential etiologic factors and various researchers have tried to improve portal hypertension by modulating these new targets. This article reviews potential new treatments in the context of portal hypertension pathophysiology concepts.
摘要
门静脉高压是肝硬化患者发病和死亡的主要原因。肝内结构扭曲和肝内血管收缩导致的肝内血管阻力增加、内脏血管扩张引起的门静脉血流增加以及侧支循环的形成被认为是门静脉高压发生的主要因素。最近，窦状隙重塑和血管生成已成为潜在的病因因素受到关注，并且各种研究人员试图通过调节这些新靶点来改善门静脉高压。本文在门静脉高压病理生理学概念的背景下综述了潜在的新治疗方法。
相似文献
1
Pathophysiology of portal hypertension and its clinical links.门静脉高压的病理生理学及其临床关联。
J Clin Exp Hepatol. 2011 Sep;1(2):87-93. doi: 10.1016/S0973-6883(11)60127-8. Epub 2011 Nov 9.
2
Pathophysiology and a Rational Basis of Therapy.病理生理学与治疗的合理依据。
Dig Dis. 2015;33(4):508-14. doi: 10.1159/000374099. Epub 2015 Jul 6.
3
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy.肝硬化门静脉高压症：病理生理机制与治疗
JHEP Rep. 2021 Jun 4;3(4):100316. doi: 10.1016/j.jhepr.2021.100316. eCollection 2021 Aug.
4
Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis.血管紧张素转化酶 2 抑制剂对肝硬化大鼠肠系膜动脉血管张力及自发性高血压大鼠血压的影响
Gastroenterology. 2013 Oct;145(4):874-884.e5. doi: 10.1053/j.gastro.2013.06.036. Epub 2013 Jun 22.
5
The beneficial effects of curcumin in cirrhotic rats with portal hypertension.姜黄素对肝硬化门静脉高压症大鼠的有益作用。
Biosci Rep. 2017 Dec 15;37(6). doi: 10.1042/BSR20171015. Print 2017 Dec 22.
6
Pathophysiology of portal hypertension.门静脉高压的病理生理学
J Physiol Pharmacol. 2008 Aug;59 Suppl 2:231-8.
7
Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?慢性肝病中的肝内血管生成和窦状隙重构：门静脉高压治疗的新靶点？
J Hepatol. 2010 Nov;53(5):976-80. doi: 10.1016/j.jhep.2010.07.004. Epub 2010 Jul 24.
8
Homocysteine deteriorates intrahepatic derangement and portal-systemic collaterals in cirrhotic rats.同型半胱氨酸使肝硬化大鼠肝内紊乱和门体侧支循环恶化。
Clin Sci (Lond). 2017 Jan 1;131(1):69-86. doi: 10.1042/CS20160470. Epub 2016 Nov 1.
9
Pharmacologic prevention of variceal bleeding and rebleeding.药物预防静脉曲张出血和再出血。
Hepatol Int. 2018 Feb;12(Suppl 1):68-80. doi: 10.1007/s12072-017-9833-y. Epub 2017 Dec 5.
10
Cellular and molecular basis of portal hypertension.门静脉高压症的细胞与分子基础
Clin Liver Dis. 2001 Aug;5(3):629-44. doi: 10.1016/s1089-3261(05)70185-9.
引用本文的文献
1
Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress.代谢功能障碍相关脂肪性肝病中心血管疾病的驱动因素：氧化应激的威胁
Front Cardiovasc Med. 2024 Oct 1;11:1469492. doi: 10.3389/fcvm.2024.1469492. eCollection 2024.
2
Improved Applicability and Diagnostic Accuracy of the Novel Spleen-Dedicated Transient Elastography Device for High-Risk Esophageal Varices.新型脾脏专用瞬时弹性成像设备在高危食管静脉曲张中的适用性及诊断准确性提高
Diagnostics (Basel). 2024 Mar 30;14(7):743. doi: 10.3390/diagnostics14070743.
3
Endoscopic variceal obturation and retrograde transvenous obliteration for acute gastric cardiofundal variceal bleeding in liver cirrhosis.肝硬化急性胃底贲门静脉曲张出血的内镜下曲张静脉闭塞和逆行经静脉闭塞治疗。
BMC Gastroenterol. 2022 Jul 26;22(1):355. doi: 10.1186/s12876-022-02428-1.
4
Overview of Complications in Cirrhosis.肝硬化并发症概述
J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1150-1174. doi: 10.1016/j.jceh.2022.04.021. Epub 2022 May 14.
5
CT hepatic arterial perfusion index does not allow stratification of the degree of esophageal varices and bleeding risk in cirrhotic patients in Child-Pugh classes A and B.CT 肝动脉灌注指数不能对 Child-Pugh A、B 级肝硬化患者食管静脉曲张程度和出血风险进行分层。
Abdom Radiol (NY). 2021 Dec;46(12):5586-5597. doi: 10.1007/s00261-021-03259-6. Epub 2021 Aug 27.
6
Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C-C Motif Chemokine Ligand 2-Mediated Angiocrine Signaling.内皮细胞 p300 通过 C-C 基序趋化因子配体 2 介导的血管生成信号促进门静脉高压和肝纤维化。
Hepatology. 2021 Jun;73(6):2468-2483. doi: 10.1002/hep.31617. Epub 2021 Apr 19.
7
Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.肝脏中的磷酸二酯酶作为肝硬化门脉高压的潜在治疗靶点。
Int J Mol Sci. 2020 Aug 28;21(17):6223. doi: 10.3390/ijms21176223.
8
Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis.贝伐单抗所致高血压在转移性结直肠癌患者中的效用：一项更新的荟萃分析。
Aging (Albany NY). 2018 Jun 21;10(6):1424-1441. doi: 10.18632/aging.101478.
9
Transitional Remodeling of the Hepatic Extracellular Matrix in Alcohol-Induced Liver Injury.酒精性肝损伤中肝细胞外基质的过渡性重塑
Biomed Res Int. 2016;2016:3162670. doi: 10.1155/2016/3162670. Epub 2016 Oct 24.
10
Targeting the renin-angiotensin system in liver fibrosis.针对肝纤维化中的肾素-血管紧张素系统
Hepatol Int. 2016 Sep;10(5):730-2. doi: 10.1007/s12072-016-9740-7. Epub 2016 May 31.
本文引用的文献
1
Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice.抑制胎盘生长因子活性可减轻肝硬化小鼠的纤维化、炎症和门静脉高压的严重程度。
Hepatology. 2011 May;53(5):1629-40. doi: 10.1002/hep.24238.
2
Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.波生坦致肝毒性：1 例病例报告并文献复习。
J Gastrointestin Liver Dis. 2011 Mar;20(1):77-80.
3
Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis.Toll样受体4信号通路在肝损伤和肝纤维化中的作用
Fibrogenesis Tissue Repair. 2010 Oct 21;3:21. doi: 10.1186/1755-1536-3-21.
4
Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?慢性肝病中的肝内血管生成和窦状隙重构：门静脉高压治疗的新靶点？
J Hepatol. 2010 Nov;53(5):976-80. doi: 10.1016/j.jhep.2010.07.004. Epub 2010 Jul 24.
5
Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease.缺氧：肝脏疾病纤维化、血管生成和癌变之间的联系。
Semin Liver Dis. 2010 Aug;30(3):258-70. doi: 10.1055/s-0030-1255355. Epub 2010 Jul 21.
6
Toll-like receptor 4 and hepatic fibrogenesis. toll 样受体 4 与肝纤维化。
Semin Liver Dis. 2010 Aug;30(3):232-44. doi: 10.1055/s-0030-1255353. Epub 2010 Jul 21.
7
Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells.神经纤毛蛋白-1 通过增强肝星状细胞中 PDGF/TGF-β 信号促进啮齿动物和人类肝脏的肝硬化。
J Clin Invest. 2010 Jul;120(7):2379-94. doi: 10.1172/JCI41203. Epub 2010 Jun 23.
8
Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver.内皮细胞 Toll 样受体 4 调控肝脏纤维化相关的血管生成。
Hepatology. 2010 Aug;52(2):590-601. doi: 10.1002/hep.23739.
9
Carvedilol for portal hypertension in patients with cirrhosis.卡维地洛用于肝硬化患者门静脉高压症的治疗。
Hepatology. 2010 Jun;51(6):2214-8. doi: 10.1002/hep.23689.
10
Neuropilin-1 regulates platelet-derived growth factor receptor signalling in mesenchymal stem cells.神经纤毛蛋白 1 调节间充质干细胞中血小板衍生生长因子受体信号转导。
Biochem J. 2010 Mar 15;427(1):29-40. doi: 10.1042/BJ20091512.
Zotero 插件